VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target
TEL AVIV, Israel, April 04, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today the presentation of new data on MOSPD2, a novel potential target in oncology. VBL's study, entitled "MOSPD2, a Newly Characterized Protein, …